Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06291376 · ClinicalTrials.gov registry record · Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
A Phase 3 study of Immunoglobulin A Nephropathy and IgAN, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT06291376: Recruiting Phase 3 study of Immunoglobulin A Nephropathy and IgAN, sponsored by Alexion Pharmaceuticals.
NCT06291376 is a Phase 3 study of Immunoglobulin A Nephropathy and IgAN that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 510 participants, above the 265-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06291376, a Phase 3 study of Immunoglobulin A Nephropathy and IgAN, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Primary Outcome
Evaluated at interim analysis only
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ravulizumab
Study Locations (20)
California
- Research Site - Loma Linda
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Orange
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - Stanford
- Research Site - Torrance
- Research Site - Valencia
Florida
- Research Site - Bay Pines
- Research Site - Miami
- Research Site - Orlando
Georgia
- Research Site - Acworth
- Research Site - Atlanta
- Research Site - Lawrenceville
Alabama
- Research Site - Alabaster
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Aurora
Iowa
- Research Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2030-07-19 |
| Phase | Phase 3 |
What NCT06291376 shows while recruiting
NCT06291376 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, above the 265-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% higher).
The record links to 2 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06291376 names 20 study sites across 7 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06291376 about?
NCT06291376 is a clinical study titled "Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)". The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
What is the current status of trial NCT06291376?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2024-03-29. Estimated completion is 2030-07-19.
What conditions does trial NCT06291376 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, IgAN.
What interventions are being tested in trial NCT06291376?
The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT06291376?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06291376 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06291376's enrollment target sits among peer trials
510 3rd of 13 higher than 11 of 13 other Immunoglobulin A Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunoglobulin A Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI